Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment
نویسندگان
چکیده
INTRODUCTION Adherence to antiretroviral (ARV) treatment for HIV-1 is crucial to achieving optimal clinical outcomes. Simplification of regimens with once-daily single-tablet regimens (STRs) can improve adherence compared to multi-tablet regimens (MTRs). This study compared real-world persistence (a proxy for treatment effectiveness and adherence) between HIV-1 infected patients receiving STRs versus MTRs. MATERIALS AND METHODS Adult HIV-1 infected patients starting their first observed ARV regimen (with at least six prior months of no ARV treatment) were identified in the MarketScan claims database (10/2008-03/2014). Persistence was measured as the time from the index regimen start date to the end of the first 90-day gap between fills for any ARV in the index regimen, or to the start date of an ARV not in the index regimen. Persistence was described using Kaplan-Meier curves and compared using log-rank tests, and Cox proportional hazards models adjusted for age, gender, insurance type, region, employment status, Charlson Comorbidity Index, other comorbidities, hospitalizations, emergency room visits and office visits. STRs were further stratified by regimen. RESULTS A total of 3257 patients (37%) initiated MTRs, and 5484 (63%) initiated STRs, including 4409 on efavirenz (EFV)/tenofovir (TDF)/emtricitabine (FTC), 484 on rilpivirine (RPV)/TDF/FTC, and 591 on elvitegravir (EVG)/cobicistat (COBI)/TDF/FTC. Median persistence was 45.0 months for STRs versus 15.2 months for MTRs (P<0.001; Figure 1). Median persistence was not reached for RPV/TDF/FTC or EVG/COBI/TDF/FTC; 31 months after RPV/TDF/FTC approval for the treatment of HIV-1 infection, more than 65% of patients who started on it remained persistent, and 19 months after EVG/COBI/TDF/FTC approval, more than 72% of patients who started on it remained persistent. Compared with MTRs, STRs had an approximately 50% lower hazard of discontinuation (adjusted hazard ratio [HR]=0.54, 95% CI 0.50-0.58). EVG/COBI/TDF/FTC and RPV/TDF/FTC had significantly longer unadjusted and adjusted persistence compared with EFV/TDF/FTC (Figure 2, Table 1). CONCLUSIONS Among HIV-1 infected patients, the use of STRs was associated with longer regimen persistence compared with MTRs. Among STRs, EVG/COBI/TDF/FTC and RPV/TDF/FTC were associated with significantly longer persistence than EFV/TDF/FTC.
منابع مشابه
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States
BACKGROUND The possibility of incorporating generics into combination antiretroviral therapy and breaking apart once-daily single-tablet regimens (STRs), may result in less efficacious medications and/or more complex regimens with the expectation of marked monetary savings. A modeling approach that assesses the merits of such policies in terms of lifelong costs and health outcomes using adheren...
متن کاملComment on: Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database.
Sir, We read with interest the article by Raffi et al. entitled Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database. We are also interested in studying HIV management in France with adherence estimation and assessment using a health insurance database. In fact, we conducted an observational study using the F...
متن کاملReal-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study
OBJECTIVES Persistence with an antiretroviral therapy (ART) regimen for HIV can be defined as the length of time a patient remains on therapy before stopping or switching. We aimed to describe ART persistence in treatment naïve patients starting therapy in the United Kingdom, and to describe differential persistence by treatment regimen. METHODS We performed a retrospective cohort study at ei...
متن کاملEffectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study
OBJECTIVES Pill burden during antiretroviral treatment (ART) is associated with worse adherence and impaired virological suppression. We compared the effectiveness, tolerance, and persistence on treatment of single tablet regimens (STRs) with non-STR once-daily regimens in patients receiving first-line ART. METHODS Retrospective analysis of naïve HIV-1 infected patients prospectively enrolled...
متن کاملOnce-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection.
Once-daily, single-tablet regimens have become integral to the management of human immunodeficiency virus type 1 infection, partly because they may improve adherence due to a lower pill burden. This article reviews the single-tablet options.
متن کامل